Should I keep holding HIMS?


I have 150 shares, average cost of $19.50 currently at a 23% loss, for the last 3 months. With Eli Lilly announcing an end to their weight loss shortage and release of Zepbound vials, it seems like HIMS lost their edge of providing compound versions of semaglutide.

They had a good earnings report recently with much increased subscribers, but not sure what their future holds.

Edit: thanks guys, I’m pretty new to investing I appreciate the advice. I sold an ITM covered call expiring 8/30 to offset some of the loss and sold the remaining 50 shares.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *